Ha Tay Pharmaceutical JSC Sustainability Profile
Ha Tay Pharmaceutical JSC, commonly referred to as Ha Tay Pharma, is a prominent player in the pharmaceutical industry, headquartered in Vietnam. Established in 1976, the company has made significant strides in the production and distribution of high-quality pharmaceutical products across various regions in Vietnam. Specialising in the development of generic medicines, Ha Tay Pharma offers a diverse range of products, including tablets, capsules, and injectables, distinguished by their adherence to stringent quality standards. The company has achieved notable milestones, including certifications that affirm its commitment to excellence in manufacturing practices. With a strong market presence, Ha Tay Pharmaceutical JSC is recognised for its innovative approach and dedication to improving healthcare outcomes, positioning itself as a trusted name in the Vietnamese pharmaceutical landscape.
DitchCarbon Score
How does Ha Tay Pharmaceutical JSC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ha Tay Pharmaceutical JSC's score of 22 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ha Tay Pharmaceutical JSC's reported carbon emissions
Ha Tay Pharmaceutical JSC, headquartered in Vietnam, currently does not have available carbon emissions data for the most recent year, nor does it report specific reduction targets or initiatives. The company has not established any Science-Based Targets Initiative (SBTi) commitments or documented climate pledges. As of now, Ha Tay Pharmaceutical JSC's climate commitments and emissions profile remain unspecified, indicating a potential area for development in their sustainability strategy. The absence of emissions data and reduction initiatives suggests that the company may be in the early stages of addressing its carbon footprint and climate impact. In the broader context of the pharmaceutical industry, companies are increasingly recognising the importance of transparency in emissions reporting and setting ambitious targets to mitigate climate change. Ha Tay Pharmaceutical JSC may benefit from aligning with industry standards and best practices to enhance its environmental performance and commitment to sustainability.
How Carbon Intensive is Ha Tay Pharmaceutical JSC's Industry?
How Carbon Intensive is Ha Tay Pharmaceutical JSC's Location?
Ha Tay Pharmaceutical JSC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ha Tay Pharmaceutical JSC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
